Drug intelligence / Profile preview

PURR-15

Development stage: Preclinical
Lead developer: The Cat Health Company

Overview

PURR-15 is an experimental veterinary therapeutic being developed by The Cat Health Company as part of its pipeline of longevity medicines for senior cats. The drug is designed to address age-related decline and associated pathologies. Although specific details regarding its molecular target and modality have not been publicly disclosed, PURR-15 is positioned within a portfolio targeting sarcopenia (muscle wasting), chronic kidney disease (CKD), and neurodegeneration. The Cat Health Company's broader mission is to extend the healthy lifespan of feline patients through targeted pharmaceutical interventions.

Beyond the preview

Go deeper on PURR-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PURR-15.

Explore the full profile